Ketamine Treatment Options in United Kingdom (Updated 5/25)

(GluEsk) Glutamate and Esketamine

NCT06432322

Completed

Esketamine is the S-enantiomer of racemic ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist. Esketamine and other antidepressant NMDA receptor antagonists are hypothesised to act by producing a rapid increase in brain glutamate release, which then stimulates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. This activity in turn is thought to restore synaptic functioning, neuroplasticity, and connectivity in brain regions involved in mood regulation, which would be... Read More

Gender:

ALL

Ages:

Between 18 years and 50 years

Trial Updated:

06/03/2025

Locations: Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, Oxfordshire

Conditions: Depression

Register for Updates

Learn More ›

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

NCT05973851

Recruiting

Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important areas of functioning. To treat MDD, there are several antidepressants available and prescribing medication is a process of trial-and-error. Guidelines do not explicitly advise on the order in which antidepressant medication... Read More

Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important areas of functioning. To treat MDD, there are several antidepressants available and prescribing medication is a process of trial-and-error. Guidelines do not explicitly advise on the order in which antidepressant medication should be prescribed. The choice of antidepressant should be tailored to the patient, while involving the patient in the decision-making process. In general, the choice for the first- and second-line treatment will be a second-generation antidepressant. Recently, esketamine nasal spray (intranasal (IN) administration) was approved for patients with treatment-resistant MDD (TRD). A patient is diagnosed with TRD when having used two antidepressants in sufficient duration and adequate dose without sufficient effect. TRD is associated with a negative impact on quality of life, higher risk for hospitalisations and suicide, comorbidities, poorer social and occupational functioning and a high carer burden. The efficacy of intranasal use of esketamine has been demonstrated in MDD subjects with treatment-resistant symptoms but also in subjects with non-treatment resistant depression, and is approved by the FDA and EMA as a third-line treatment. Besides the registered esketamine nasal spray, which is not available in all countries to all patients because of the high costs, off-label utilization of (es)ketamine infusions (IV) is growing extensively over time to treat TRD. Research conducted so far indicates an unequivocal initial substantial response to (es)ketamine IV in MDD populations, regardless of whether or not patients suffer from treatment resistant MDD. However, until now, there has not been a study investigating this in a sufficiently large population. This may be a unique opportunity to potentially prevent patients progressing into a treatment resistant illness stage. The potential implications of the results of the current study are the prevention of unnecessary trials of ineffective treatments, reducing subject burden substantially, as well as a reduction of healthcare and societal costs. Read Less

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

05/13/2025

Locations: Medical University Innsbruck, Innsbruck, Not set +11 locations

Conditions: Major Depressive Disorder, Treatment Resistant Depression

Register for Updates

Learn More ›

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287

Completed

The purpose of this open-label, multicenter study is to assess the long term safety and efficacy of intranasal esketamine plus an oral antidepressant in participants with treatment-resistant depression (TRD).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Not set, New Haven, Connecticut +109 locations

Not set, New Haven, Connecticut

Not set, Miami, Florida

Not set, Marietta, Georgia

Not set, Iowa City, Iowa

Not set, Wichita, Kansas

Not set, Baltimore, Maryland

Not set, Watertown, Massachusetts

Not set, Cedarhurst, New York

Not set, New York, New York

Not set, Staten Island, New York

Not set, Cincinnati, Ohio

Not set, Allentown, Pennsylvania

Not set, Charleston, South Carolina

Not set, Dallas, Texas

Not set, Wichita Falls, Texas

Not set, Richland, Washington

Not set, Banfield, Not set

Not set, Buenos Aires, Not set

Not set, Ciudad Autonoma de Buenos Aires, Not set

Not set, Cordoba, Not set

Not set, La Plata, Not set

Not set, Mendoza, Not set

Not set, Rosario, Not set

Not set, Adelaide, Not set

Not set, Caulfield, Not set

Not set, Frankston, Not set

Not set, Melbourne, Not set

Not set, Innsbruck, Not set

Not set, Vienna, Not set

Not set, Brugge, Not set

Not set, Hasselt, Not set

Not set, Belo Horizonte, Not set

Not set, Fortaleza, Not set

Not set, Recife, Not set

Not set, Rio de Janeiro, Not set

Not set, Santo André, Not set

Not set, Sao Jose do Rio Preto, Not set

Not set, São Paulo, Not set

Not set, Bourgas, Not set

Not set, Kardzhali, Not set

Not set, Kazanlak, Not set

Not set, Pazardzhik, Not set

Not set, Pleven, Not set

Not set, Plovdiv, Not set

Not set, Rousse, Not set

Not set, Sofia, Not set

Not set, Varna, Not set

Not set, Helsinki, Not set

Not set, Kuopio, Not set

Not set, Paris, Not set

Not set, Poitiers, Not set

Not set, Toulon, Not set

Not set, TOURS cedex 9, Not set

Not set, Berlin, Not set

Not set, Bochum, Not set

Not set, Oranienburg-Sachsenhausen, Not set

Not set, Gwangju, Not set

Not set, Gyeonggi-do, Not set

Not set, Seoul, Not set

Not set, Kaunas, Not set

Not set, Silute, Not set

Not set, Vilnius, Not set

Not set, Ipoh, Not set

Not set, Johor Bahru, Not set

Not set, Kuala Lumpur, Not set

Not set, Acapulco, Not set

Not set, Durango, Not set

Not set, Mexico City, Not set

Not set, Mexico, Not set

Not set, Monterrey, Not set

Not set, Gdansk, Not set

Not set, Cape Town, Not set

Not set, Garsfontein, Not set

Not set, Pretoria, Not set

Not set, Badajoz, Not set

Not set, Bilbao, Not set

Not set, Madrid, Not set

Not set, Ourense, Not set

Not set, Oviedo, Not set

Not set, Sant Boi de Llobregat, Not set

Not set, Torrevieja, Not set

Not set, Valencia, Not set

Not set, Zamora, Not set

Not set, Goteborg, Not set

Not set, Halmstad, Not set

Not set, Lund, Not set

Not set, Skovde, Not set

Not set, Solna, Not set

Not set, Stockholm, Not set

Not set, Umea, Not set

Not set, Kaohsiung, Not set

Not set, New Taipei City, Not set

Not set, Taichung, Not set

Not set, Tainan, Not set

Not set, Taipei, Not set

Not set, Taoyuan County, Not set

Not set, Ankara, Not set

Not set, Bursa, Not set

Not set, Gaziantep, Not set

Not set, Istanbul, Not set

Not set, Kocaeli, Not set

Not set, Manisa, Not set

Not set, Bristol, Not set

Not set, Chesterfield, Not set

Not set, Derby, Not set

Not set, London, Not set

Not set, Middlesbrough, Not set

Not set, Northampton, Not set

Not set, Oxford, Not set

Not set, Preston, Not set

Conditions: Treatment-resistant Depression

Register for Updates

Learn More ›

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104

Completed

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +176 locations

Not set, Birmingham, Alabama

Not set, Little Rock, Arkansas

Not set, Garden Grove, California

Not set, Glendale, California

Not set, Oakland, California

Not set, Orange, California

Not set, San Diego, California

Not set, San Rafael, California

Not set, Hartford, Connecticut

Not set, New Haven, Connecticut

Not set, Gainesville, Florida

Not set, Miami, Florida

Not set, Orlando, Florida

Not set, Atlanta, Georgia

Not set, Chicago, Illinois

Not set, Hoffman Estates, Illinois

Not set, Joliet, Illinois

Not set, Maywood, Illinois

Not set, Skokie, Illinois

Not set, Iowa City, Iowa

Not set, Wichita, Kansas

Not set, Lake Charles, Louisiana

Not set, Shreveport, Louisiana

Not set, Baltimore, Maryland

Not set, Gaithersburg, Maryland

Not set, Boston, Massachusetts

Not set, New Bedford, Massachusetts

Not set, Watertown, Massachusetts

Not set, Worcester, Massachusetts

Not set, Rochester Hills, Michigan

Not set, O'Fallon, Missouri

Not set, Saint Charles, Missouri

Not set, Omaha, Nebraska

Not set, Cedarhurst, New York

Not set, New York, New York

Not set, Staten Island, New York

Not set, Hickory, North Carolina

Not set, Cincinnati, Ohio

Not set, Oklahoma City, Oklahoma

Not set, Allentown, Pennsylvania

Not set, Media, Pennsylvania

Not set, Philadelphia, Pennsylvania

Not set, Lincoln, Rhode Island

Not set, Providence, Rhode Island

Not set, Charleston, South Carolina

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Houston, Texas

Not set, Wichita Falls, Texas

Not set, Charlottesville, Virginia

Not set, Waukesha, Wisconsin

Not set, Banfield, Not set

Not set, Ciudad Autonoma de Buenos Aires, Not set

Not set, Ciudad Autónoma De Buenos Aires, Not set

Not set, Cordoba, Not set

Not set, La Plata, Not set

Not set, Mendoza, Not set

Not set, Rosario, Not set

Not set, Caulfield, Not set

Not set, Elizabeth Vale, Not set

Not set, Frankston, Not set

Not set, Vienna, Not set

Not set, Aalst, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Heusden-Zolder, Not set

Not set, Liège, Not set

Not set, Yvoir, Not set

Not set, Belo Horizonte, Not set

Not set, Curitiba, Not set

Not set, Fortaleza, Not set

Not set, Passo Fundo, Not set

Not set, Porto Alegre, Not set

Not set, Recife, Not set

Not set, Rio de Janeiro, Not set

Not set, Sao Bernardo do Campo, Not set

Not set, Sao Paulo, Not set

Not set, Bourgas, Not set

Not set, Kardzhali, Not set

Not set, Pazardzhik, Not set

Not set, Pleven, Not set

Not set, Plovdiv, Not set

Not set, Rousse, Not set

Not set, Sofia, Not set

Not set, Varna, Not set

Not set, Vancouver, British Columbia

Not set, Kingston, Ontario

Not set, Ottawa, Ontario

Not set, Toronto, Ontario

Not set, Brno, Not set

Not set, Plzen, Not set

Not set, Prague, Not set

Not set, Praha 10, Not set

Not set, Praha 2, Not set

Not set, Praha 6, Not set

Not set, Tallinn, Not set

Not set, Tartu, Not set

Not set, Kuopio, Not set

Not set, Clermont-Ferrand Cedex 1, Not set

Not set, Douai, Not set

Not set, Nantes, Not set

Not set, Nîmes, Not set

Not set, Paris, Not set

Not set, Poitiers Cedex, Not set

Not set, Toulon Cedex, Not set

Not set, Berlin, Not set

Not set, Bochum, Not set

Not set, Mainz, Not set

Not set, Mittweida, Not set

Not set, Oranienburg, Not set

Not set, Pfaffenhofen, Not set

Not set, Budapest, Not set

Not set, Debrecen, Not set

Not set, Gyor, Not set

Not set, Pecs, Not set

Not set, Sopron, Not set

Not set, Szekszárd, Not set

Not set, Vác, Not set

Not set, Gwangju, Not set

Not set, Seoul, Not set

Not set, Kaunas, Not set

Not set, Kuala Lumpur, Not set

Not set, Guadalajara, Not set

Not set, Leon, Not set

Not set, Mexico City, Not set

Not set, Mexico, Not set

Not set, Monterrey, Not set

Not set, San Luis Potosi, Not set

Not set, Belchatow, Not set

Not set, Bialystok, Not set

Not set, Bydgoszcz, Not set

Not set, Gdansk, Not set

Not set, Leszno, Not set

Not set, Lublin, Not set

Not set, Warszawa, Not set

Not set, Bratislava, Not set

Not set, Liptovsky Mikulas, Not set

Not set, Rimavska Sobota, Not set

Not set, Roznava, Not set

Not set, Svidnik, Not set

Not set, Cape Town, Not set

Not set, Pretoria, Not set

Not set, Welgemoed, Not set

Not set, Alcorcón, Not set

Not set, Barcelona, Not set

Not set, Bilbao, Not set

Not set, Madrid, Not set

Not set, Oviedo, Not set

Not set, Palma, Not set

Not set, Pamplona, Not set

Not set, Sabadell, Not set

Not set, Salamanca, Not set

Not set, Sant Boi de Llobregat, Not set

Not set, Torrevieja, Not set

Not set, Vitoria-Gasteiz, Not set

Not set, Zamora, Not set

Not set, Halmstad, Not set

Not set, Lund, Not set

Not set, Skövde, Not set

Not set, Stockholm, Not set

Not set, Kaohsiung, Not set

Not set, New Taipei, Not set

Not set, Taichung, Not set

Not set, Taipei, Not set

Not set, Taoyuan, Not set

Not set, Adana, Not set

Not set, Ankara, Not set

Not set, Bursa, Not set

Not set, Istanbul, Not set

Not set, Kucukcekmece/Istanbul, Not set

Not set, Oanakkale, Not set

Not set, Samsun, Not set

Not set, Chesterfield, Not set

Not set, Derby, Not set

Not set, London, Not set

Not set, Northampton, Not set

Not set, Oxford, Not set

Conditions: Depressive Disorder, Treatment-Resistant

Register for Updates

Learn More ›

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186

Completed

The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.

Gender:

ALL

Ages:

65 years and above

Trial Updated:

04/25/2025

Locations: Not set, San Diego, California +69 locations

Not set, San Diego, California

Not set, New Haven, Connecticut

Not set, Miami, Florida

Not set, Marietta, Georgia

Not set, Iowa City, Iowa

Not set, Baltimore, Maryland

Not set, Watertown, Massachusetts

Not set, New York, New York

Not set, Staten Island, New York

Not set, Cincinnati, Ohio

Not set, Allentown, Pennsylvania

Not set, Dallas, Texas

Not set, Wichita Falls, Texas

Not set, Charlottesville, Virginia

Not set, Richland, Washington

Not set, Aalst, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Hasselt, Not set

Not set, Heusden-Zolder, Not set

Not set, Liège, Not set

Not set, Belo Horizonte, Not set

Not set, Fortaleza, Not set

Not set, Rio de Janeiro, Not set

Not set, Santo André, Not set

Not set, Sao Jose do Rio Preto, Not set

Not set, Sao Paulo, Not set

Not set, São Paulo, Not set

Not set, Bourgas, Not set

Not set, Kardzhali, Not set

Not set, Sofia, Not set

Not set, Varna, Not set

Not set, Helsinki, Not set

Not set, Kuopio, Not set

Not set, Issy-les-Moulineaux, Not set

Not set, La Tronche, Not set

Not set, Nice, Not set

Not set, Nimes Cedex 9, Not set

Not set, Paris, Not set

Not set, Poitiers, Not set

Not set, Toulon, Not set

Not set, Toulouse, Not set

Not set, TOURS cedex 9, Not set

Not set, Kaunas, Not set

Not set, Silute, Not set

Not set, Vilnius, Not set

Not set, Belchatow, Not set

Not set, Bydgoszcz, Not set

Not set, Gdansk, Not set

Not set, Torun, Not set

Not set, Tuszyn, Not set

Not set, Cape Town, Not set

Not set, Garsfontein, Not set

Not set, Pretoria, Not set

Not set, Badajoz, Not set

Not set, Bilbao, Not set

Not set, Madrid, Not set

Not set, Ourense, Not set

Not set, Sant Boi de Llobregat, Not set

Not set, Torrevieja, Not set

Not set, Zamora, Not set

Not set, Goteborg, Not set

Not set, Halmstad, Not set

Not set, Lund, Not set

Not set, Skövde, Not set

Not set, Solna, Not set

Not set, Stockholm, Not set

Not set, Derbyshire, Not set

Not set, Oxford, Not set

Not set, Preston, Not set

Conditions: Depressive Disorder, Treatment-Resistant

Register for Updates

Learn More ›

Synaptic Imaging and Network Activity in Treatment Resistant Depression

NCT05870501

Completed

The main aim of this research is to explore the effects that ketamine has on the functional connectivity of the brain in participants with treatment resistant depression (TRD). This study will investigate the relationship between these changes and response to treatment as measured by clinical scales, as well as examining drug induced changes in reward and emotion based brain activity, structural connectivity, cerebral blood flow, cognition, metabolism and blood markers of brain plasticity.

Gender:

ALL

Ages:

Between 18 years and 55 years

Trial Updated:

11/15/2024

Locations: The Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, Not set

Conditions: Depressive Disorder, Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant, Bipolar Disorder, Bipolar Disorder I, Bipolar Disorder II, Mood Disorders, Anhedonia

Register for Updates

Learn More ›

Preventing Pain After Heart Surgery

NCT01480765

Completed

The use of pre-emptive analgesia to prevent pain following sternotomy for cardiac surgery

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

11/04/2024

Locations: Pain and Ananesthesia Research Centre, Barts and The London NHS Trust, London, Not set

Conditions: Pain, Hyperalgesia, Chronic Illness, Neuropathic Pain

Register for Updates

Learn More ›

Glutamate Emotion Memory Study

NCT05809609

Recruiting

Clinical depression often includes a pessimistic view of things which have happened in the past and an impairment in the ability to experience pleasure or looking forward to things. A licensed drug called ketamine affects the levels of glutamate, a chemical messenger in the brain, and has been used as a treatment particularly for depression which hasn't got better with other types of medication. Glutamate plays a role in learning and memory so the investigators are interested in understanding ho... Read More

Gender:

ALL

Ages:

Between 20 years and 60 years

Trial Updated:

05/20/2024

Locations: Department of Psychiatry, University of Oxford, Oxford, Not set

Conditions: Treatment Resistant Depression, Depression, Major Depressive Disorder

Register for Updates

Learn More ›

Reward Emotion Learning and Ketamine Study

NCT04850911

Unknown

Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully described. Work in the animal literature and research in humans is suggestive of specific effects on anhedonia and memory reconsolidation. In this study the investigators will further explore the effects of ketamine on learning and memory as well as measuring the associated changes at neural level in a sample of healthy volunteers. Participants will be assi... Read More

Gender:

ALL

Ages:

Between 18 years and 45 years

Trial Updated:

03/24/2023

Locations: University of Oxford, Oxford, Not set

Conditions: Depression, Major Depressive Disorder, Treatment Resistant Depression

Register for Updates

Learn More ›

Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine

NCT04977674

Completed

The overarching aim of this research is to determine the acute effects of ketamine on brain glutamate, functional connectivity and cerebral blood flow in treatment-resistant depression, explore whether the effects are attenuated by the opioid receptor antagonist naltrexone and relate these findings to antidepressant response.

Gender:

ALL

Ages:

Between 18 years and 50 years

Trial Updated:

02/28/2023

Locations: King's College London, London, Not set

Conditions: Depressive Disorder, Treatment-Resistant

Register for Updates

Learn More ›

Ketamine for Reduction of Alcoholic Relapse

NCT02649231

Completed

96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation. Patients will be assessed at 3 and 6 months on a range of psychological and biological variables. Primary endpoints will be % days abstinent at 6 months and relapse rates at 6 months. Secondary endpoints include depressive symptoms, craving, quality of life.

Gender:

ALL

Ages:

Between 18 years and 60 years

Trial Updated:

09/09/2021

Locations: NIHR Exeter Clinical Research Facility, Exeter, Not set +1 locations

Conditions: Primary Alcohol Use Disorder

Register for Updates

Learn More ›

Low Dose Peri-operative IV Ketamine for Chronic Post-surgery Pain Prevention

NCT01296347

Completed

This study will test the null hypothesis that low-dose ketamine given peri-operatively will have no effect on the development of chronic post-surgical pain, in patients undergoing thoracotomy or video assisted thoracic surgery (VATS) procedures A double-blind, randomised placebo-controlled trial will be used to test the null hypothesis. Potential participants due to undergo either thoracotomy or video assisted thoracic surgery (VATS) will be identified by the collaborating thoracic surgeons in... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/22/2019

Locations: Imperial College Healthcare NHS Trust, London, Not set

Conditions: Chronic Postoperative Pain

Register for Updates

Learn More ›

Ketamine Treatment Options in United Kingdom

Match to Clinical Trials